Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Fennec Pharmaceuticals (FENC) EPS (Basic) (2016 - 2025)

Fennec Pharmaceuticals (FENC) has disclosed EPS (Basic) for 15 consecutive years, with -$0.03 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, EPS (Basic) rose 85.71% year-over-year to -$0.03, compared with a TTM value of -$0.26 through Sep 2025, down 550.0%, and an annual FY2024 reading of -$0.02, up 96.67% over the prior year.
  • EPS (Basic) was -$0.03 for Q3 2025 at Fennec Pharmaceuticals, up from -$0.11 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.47 in Q1 2024 and bottomed at -$0.4 in Q4 2022.
  • Average EPS (Basic) over 5 years is -$0.13, with a median of -$0.16 recorded in 2021.
  • Peak annual rise in EPS (Basic) hit 304.35% in 2024, while the deepest fall reached 200.0% in 2024.
  • Year by year, EPS (Basic) stood at -$0.16 in 2021, then plummeted by 150.0% to -$0.4 in 2022, then soared by 75.0% to -$0.1 in 2023, then grew by 20.0% to -$0.08 in 2024, then surged by 62.5% to -$0.03 in 2025.
  • Business Quant data shows EPS (Basic) for FENC at -$0.03 in Q3 2025, -$0.11 in Q2 2025, and -$0.04 in Q1 2025.